{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:45:55Z","timestamp":1768841155735,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40120-022-00332-0","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T16:02:47Z","timestamp":1645545767000},"page":"711-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patterns of Daily Motor-Symptom Control with Carbidopa\/Levodopa Enteral Suspension Versus Oral Carbidopa\/Levodopa Therapy in Advanced Parkinson\u2019s Disease: Clinical Trial Post Hoc Analyses"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-6466","authenticated-orcid":false,"given":"Rajesh","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7441-0967","authenticated-orcid":false,"given":"Jason","family":"Aldred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niodita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Terasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Garcia-Horton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasanna L.","family":"Kandukuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek S.","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yash J.","family":"Jalundhwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-5706","authenticated-orcid":false,"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"issue":"11","key":"332_CR1","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P. Parkinson\u2019s disease symptoms: the patient\u2019s perspective. Mov Disord. 2010;25(11):1646\u201351.","journal-title":"Mov Disord"},{"issue":"2","key":"332_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75\u201381.","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"332_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677\u201387.","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"332_CR4","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S1353-8020(09)70005-7","volume":"15","author":"F Stocchi","year":"2009","unstructured":"Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2009;15(Suppl 1):S9\u201315.","journal-title":"Parkinsonism Relat Disord"},{"key":"332_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","volume":"51","author":"KL Chou","year":"2018","unstructured":"Chou KL, Stacy M, Simuni T, et al. The spectrum of \u201coff\u201d in Parkinson\u2019s disease: what have we learned over 40 years? Parkinsonism Relat Disord. 2018;51:9\u201316.","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"332_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/mds.20602","volume":"20","author":"KA Grosset","year":"2005","unstructured":"Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson\u2019s disease. Mov Disord. 2005;20(11):1502\u20137.","journal-title":"Mov Disord"},{"issue":"Suppl 11","key":"332_CR7","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J. Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations. Mov Disord. 2005;20(Suppl 11):S11\u20136.","journal-title":"Mov Disord"},{"issue":"11","key":"332_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","volume":"20","author":"A Rizos","year":"2014","unstructured":"Rizos A, Martinez-Martin P, Odin P, et al. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson\u2019s disease: an international multicenter study. Parkinsonism Relat Disord. 2014;20(11):1231\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"332_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord. 2005;20(2):224\u201330.","journal-title":"Mov Disord"},{"issue":"1","key":"332_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/A:1008928321652","volume":"9","author":"AM Damiano","year":"2000","unstructured":"Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson\u2019s disease: assessing patient health-related quality of life. Qual Life Res. 2000;9(1):87\u2013100.","journal-title":"Qual Life Res"},{"issue":"11","key":"332_CR11","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00702-012-0796-9","volume":"119","author":"A Khlebtovsky","year":"2012","unstructured":"Khlebtovsky A, Rigbi A, Melamed E, et al. Patient and caregiver perceptions of the social impact of advanced Parkinson\u2019s disease and dyskinesias. J Neural Transm (Vienna). 2012;119(11):1367\u201371.","journal-title":"J Neural Transm (Vienna)"},{"key":"332_CR12","first-page":"57","volume":"6","author":"N Tambasco","year":"2016","unstructured":"Tambasco N, Simoni S, Nigro P, Paolini Paoletti F, Marsili E, Calabresi P. Morning akinesia in Parkinson\u2019s disease: challenges and solutions. Res Rev Parkinsonism. 2016;6:57\u201363.","journal-title":"Res Rev Parkinsonism"},{"issue":"Suppl 4","key":"332_CR13","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/S1353-8020(09)70844-2","volume":"15","author":"A Antonini","year":"2009","unstructured":"Antonini A, Odin P. Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson\u2019s disease. Parkinsonism Relat Disord. 2009;15(Suppl 4):S97-100.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"332_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/00002826-200305000-00010","volume":"26","author":"D Nyholm","year":"2003","unstructured":"Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003;26(3):156\u201363.","journal-title":"Clin Neuropharmacol"},{"key":"332_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.parkreldis.2020.05.001","volume":"76","author":"RF Pfeiffer","year":"2020","unstructured":"Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2020;76:63\u201371.","journal-title":"Parkinsonism Relat Disord"},{"issue":"s1","key":"332_CR16","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-181476","volume":"8","author":"DJ van Wamelen","year":"2018","unstructured":"van Wamelen DJ, Grigoriou S, Chaudhuri KR, Odin P. Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson\u2019s disease. J Parkinsons Dis. 2018;8(s1):S65\u201372.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"332_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol"},{"issue":"3","key":"332_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3233\/JPD-181565","volume":"9","author":"RA Hauser","year":"2019","unstructured":"Hauser RA, Kremens DE, Elmer LW, et al. Prevalence of dyskinesia and OFF by 30-minute intervals through the day and assessment of daily episodes of dyskinesia and OFF: novel analyses of diary data from Gocovri pivotal trials. J Parkinsons Dis. 2019;9(3):591\u2013600.","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"332_CR19","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1136\/jnnp.2003.034553","volume":"75","author":"P Chana","year":"2004","unstructured":"Chana P, Kuntsmann C, Reyes-Parada M, Saez-Briones P. Delayed early morning turn \u201cON\u201d in response to a single dose of levodopa in advanced Parkinson\u2019s disease: pharmacokinetics should be considered. J Neurol Neurosurg Psychiatry. 2004;75(12):1782\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"332_CR20","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1007\/s00702-014-1259-2","volume":"121","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Stirpe P. The relevance of dopaminergic level in nocturnal disability in Parkinson\u2019s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms. J Neural Transm (Vienna). 2014;121(Suppl 1):S79-83.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"332_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/mdc3.12350","volume":"4","author":"S Isaacson","year":"2017","unstructured":"Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson\u2019s disease. Mov Disord Clin Pract. 2017;4(1):78\u201383.","journal-title":"Mov Disord Clin Pract"},{"issue":"10","key":"332_CR22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1586\/14737175.6.10.1403","volume":"6","author":"D Nyholm","year":"2006","unstructured":"Nyholm D. Enteral levodopa\/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson\u2019s disease. Expert Rev Neurother. 2006;6(10):1403\u201311.","journal-title":"Expert Rev Neurother"},{"issue":"980","key":"332_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","volume":"83","author":"B Thanvi","year":"2007","unstructured":"Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson\u2019s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 2007;83(980):384\u20138.","journal-title":"Postgrad Med J"},{"issue":"12","key":"332_CR24","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","volume":"12","author":"M Pechevis","year":"2005","unstructured":"Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson\u2019s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005;12(12):956\u201363.","journal-title":"Eur J Neurol"},{"key":"332_CR25","doi-asserted-by":"crossref","unstructured":"Pahwa R, Isaacson SH. Pathophysiology, patient burden, and recognition of OFF episodes of parkinson disease. J Clin Psychiatry. 2020;81(6):SU19004BR1C.","DOI":"10.4088\/JCP.SU19004BR1C"},{"issue":"2","key":"332_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JPD-161042","volume":"7","author":"AA Othman","year":"2017","unstructured":"Othman AA, Rosebraugh M, Chatamra K, Locke C, Dutta S. Levodopa-carbidopa intestinal gel pharmacokinetics: lower variability than oral levodopa\u2013carbidopa. J Parkinsons Dis. 2017;7(2):275\u20138.","journal-title":"J Parkinsons Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00332-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T14:34:57Z","timestamp":1652279697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00332-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00332-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}